Atopic Dermatitis

New phase 3 data found that 70% of patients with atopic dermatitis achieved EASI-75 following treatment with lebrikizumab and topical corticosteroids

A new systematic review found that patients with the dermatologic condition experienced moderate impairment of health-related quality of life and emotions.

Conversely, age was shown to have a negative association, as did the highest category of physical activity.

Botulin toxin was first approved by the FDA in 2002 for cosmetic reasons.

Differences in rosacea subtypes were also observed regarding patient sex, continent of origin, and the year of publication.

Dr. Karan Lal provides essential information on rosacea, which the National Rosacea Society estimates to affect 16 million people in the United States.

The investigative team also observed a significant association between psoriasis, IBS, anxiety, and depression in patients with diabetes and rosacea.

Previous research has suggested that current rosacea therapies can also induce burning or stinging sensations in patients.

Among the different rosacea phenotypes included in the study, no statistical difference in ANAs was observed.

New 5-year data raises concerns of over-diagnosis from melanoma screening.

The highest epidermal thickness was calculated for Asian skin at the forehead while the lowest epidermal thickness was for African skin at the dorsal forearm.

Significantly higher incidence rates of alopecia areata were seen in Hispanic children.

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

Dr. Karan Lal offers insights into diagnosing various forms of rosacea as well as common treatment methods.

This is the first topical treatment approved by the FDA for facial angiofibroma associated with tuberous sclerosis complex in adults and children 6 years and older.

Previous research suggested that inpatient dermatology services not only improved diagnostic accuracy but reduced readmissions.

A consensus was reached on nearly all proposals in the eDelphi study, which members said could be used to establish a clear dosing regimen for methotrexate.

Data from the ADhere studies found that lebrikizumab was well tolerated in patients with atopic dermatitis.

New phase 2 data from the KARE study presented at AAD found that the therapy improved itch severity and sleep in patients with atopic dermatitis and pruritis.

Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.

Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.

Data from a pair of phase 3 trials concluded that oral baricitinib was superior to placebo for patients with severe alopecia areata for hair regrowth at 36 weeks.

Dupilumab is the first biologic to show positive phase 3 results in patients with prurigo nodularis.

New data suggest that treatment with dupilumab does not increase the risk of COVID-19 infection in patients with atopic diseases.

The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.